Lactobacillus rhamnosus LRa05 Ameliorate Hyperglycemia through a Regulating Glucagon-Mediated Signaling Pathway and Gut Microbiota in Type 2 Diabetic Mice.
- 2021-08-03
- Journal of Agricultural and Food Chemistry 69(31)
- Tao Wu
- Yongli Zhang
- W. Li
- Yunjiao Zhao
- Hairong Long
- Esther Mwizerwa Muhindo
- R. Liu
- Wenjie Sui
- Qian Li
- M. Zhang
- PubMed: 34340304
- DOI: 10.1021/acs.jafc.1c02925
Study Design
- Type
- Clinical Trial
- Population
- T2DM mice
- Methods
- In vivo experiment with mice.
- Animal Study
Abstract
In this study, we aimed to explore the antidiabetic effects of Lactobacillus rhamnosus LRa05 on glucose metabolism and gut microbiota in type 2 diabetes mellitus (T2DM) mice. Our data indicated that the fasting blood glucose levels were reduced by 53.5% after treatment with LRa05 at a dose of 109 CFU·day-1. Meanwhile, LRa05 attenuated insulin resistance, relieved hepatic oxidative stress, and alleviated metabolic lipopolysaccharide-related inflammation in T2DM mice. LRa05 promoted the expression of glucose transporter 2, while it inhibited the expression of glucagon receptor, glucose-6-phosphatase, cellular adenosine-3'-5'-cyclic monophosphate-dependent protein kinase, and phosphoenolpyruvate carboxykinase in diabetic mice. Meanwhile, LRa05 reshaped gut microbiota, resulting in increased short-chain fatty acid bacteria (Alloprevotella and Bacteroides) and decreased proinflammatory bacteria (Odoribacter and Mucispirillum). Thus, LRa05 may be used as a functional food supplement for modulating the disorder glucose metabolism and gut microbiota in T2DM.
Keywords: Lactobacillus rhamnosus LRa05; T2DM; anti-hyperglycemic; glucagon signaling pathway; gut microbiota.